Science, medicine, and the future. Allergic disorders.

PubWeight™: 1.27‹?› | Rank: Top 10%

🔗 View Article (PMC 1117434)

Published in BMJ on January 22, 2000

Authors

S T Holgate1

Author Affiliations

1: Medical Specialties, Southampton General Hospital, Southampton SO16 6YD. sth@soton.ac.uk

Articles cited by this

Requirement for IL-13 independently of IL-4 in experimental asthma. Science (1998) 10.76

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 8.38

The inverse association between tuberculin responses and atopic disorder. Science (1997) 7.46

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med (1997) 4.06

Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med (1999) 3.36

Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest (1997) 2.68

Role of microbial burden in aetiology of allergy and asthma. Lancet (1999) 1.92

Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. Mol Cell (1999) 1.88

Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol (1999) 1.75

Reversing the trend: reducing the prevalence of asthma. J Allergy Clin Immunol (1999) 1.50

Mechanisms of deficient interferon-gamma production in atopic diseases. Clin Exp Allergy (1999) 1.48

Allergy treatment with a peptide vaccine. Lancet (1990) 1.45

Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology (1998) 1.44

Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol (1997) 1.29

Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur J Biochem (1994) 1.20

Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol (1998) 1.17

An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol (1998) 0.94

Injection of anti-IgE antibodies will suppress IgE and allergic symptoms. Allergy (1999) 0.87

Epitope-specific antibody response to IgE by mimotope immunization. J Immunol (1998) 0.87

Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell-dependent costimulatory signals. J Immunol (1997) 0.87

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy (1998) 0.85

Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation. Allergy (1997) 0.85

Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor. Int Arch Allergy Immunol (1996) 0.85

Chemokines and IL-5: major players of eosinophil recruitment in asthma. Clin Exp Allergy (1999) 0.82